The drug has already been under trial and the results were spectacular, according to Novartis, the company that produces it.
The experts are quite enthusiastic about the possibility of having such successful treatment available on the market.
“For those of us who have been practicing in heart failure, we’ve been waiting for a day like for like 15 years, which was the last time we had a major breakthrough in the treatment of systolic heart failure. It reduces heart failure hospitalizations and it helps people with heart failure live longer, ” said Dr. Sean Pinney, who is the Director of the Advanced Heart Failure and Transplantation Program at The Mount Sinai Hospital.
Those who have tested the drug say that it is so efficient that it is able to reduce mortality associated with heart failure, as well as hospitalizations to more than 20 percent. This represents a huge step forward, as it does not only give patients a chance to live longer but it helps the economy as well.
Right now, the numbers show that about $35 million go to hospitalizations linked to heart failure, given the fact that this condition is the leading cause of hospitalizations.
Thus, the drug could help the authorities save a lot of money in the future, even if the drug is not the cheapest thing one can imagine. According to Novartis, treatment would cost a patient about $ 4,500 per year, considering that he or she takes two pills every day.
However, this sum is a few times lower than other treatments available and it saves a lot of money if the patient manages to avoid hospitalization.
During the trial, which was the largest one ever for a heart failure drug, 8,400 were divided into groups and given various treatments, including Entresto, which is also known by its trial name – LCZ696.
The researchers noticed that the drug had a 21.8 percent death or hospitalization rate, compared to other drugs, which had a 26.5 percent rate after 27 months of treatment.
However, because the drug is quite powerful, there are also some side effects associated with it. These are similar to the ones recorded with other heart failure drugs and include low blood pressure, poor kidney function or higher potassium levels.
The experts warn that black people are more likely to be exposed to risks when taking Entresto because they might not tolerate the lower blood pressure well enough, but tests still need to be carried out further.
Image Source: newsroom.novartis